Expression of Vascular Endothelial Growth Factor in Capillary Hemangioblastoma

doi:10.1006/bbrc.1993.1885

Biochemical and Biophysical Research Communications

Volume 194, Issue 2, 30 July 1993, Pages 749-755

https://doi.org/10.1006/bbrc.1993.1885 Get rights and content

Abstract

The gene expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen, was examined in capillary hemangioblastomas which are composed of abundant microvasculature and primitive angiogenic elements represented by stromal cells. Northern blot and in situ hybridization analyses showed that the VEGF mRNA was highly expressed in the stromal cells, but not in the endothelial cells. Reverse transcription/PCR analysis revealed that the VEGF mRNA species expressed in the stromal cells were the shorter splicing forms. VEGF₁₂₁ and VEGF₁₆₅, which are potent to be secreted from cells and the longer splicing form, VEGF₁₈₉, which is predominantly cell-associated. Our findings suggest that VEGF secreted from the stromal cells plays an important role in the endothelial cell proliferation in capillary hemangioblastomas.

References (0)

Cited by (89)

Filum Terminale: A Comprehensive Review with Anatomical, Pathological, and Surgical Considerations
2022, World Neurosurgery
Citation Excerpt :
The origin of extramedullary hemangioblastomas is still unclear. Few studies indicated that the vascular endothelial growth factor secreted by stromal cells plays an important role in endothelial cell proliferation.72 Under the microscope, the stromal tumor cells have abundant foamy cytoplasm with lobulated nuclei surrounded by a rich capillary network.
The conus medullaris is the distal tapering end of the spinal cord, and the filum terminale (FT) is regarded as a bundle of nonfunctional fibrous tissue; therefore, some scholars call it the spinal ligament, while others describe the human FT as “remnants of the spinal cord.” It was later found that in the human spinal cord, the FT is composed of an intradural segment and an epidural segment, and the end of the FT is connected to the coccyx periosteum. Because some nerve tissue is also found in the FT, as research progresses, FT may have the potential for transplantation. A lack of exhaustive overviews on the FT in the present literature prompted us to conduct this review. Considering that a current comprehensive review seemed to be the need of the hour, herein, we attempted to summarize previous research and theories on the FT, elucidate its anatomy, and understand its pathological involvement in various diseases.
Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors
2020, Experimental and Molecular Pathology
Citation Excerpt :
VEGF-A and VEGFRs are associated with hypervascularization and cystic formation. Recent reports have demonstrated that von Hippel-Lindau (VHL) loss of function leads to up-regulation of hypoxia-inducible genes, such as VEGF-A (Böhling et al., 1996; Iliopoulos et al., 1996; Krieg et al., 1998; Morii et al., 1993; Wizigmann-Voos et al., 1995). Other reports have demonstrated that strong expressions for VEGFRs (VEGFR2 > VEGFR1) were observed in the endothelial cells and the clusters of stromal cells in all sporadic and VHL-associated hemangioblastomas, leading to growth of the cystic component (Flores-Stadler et al., 1997; Laviv et al., 2019; Pierscianek et al., 2017; Wizigmann-Voos et al., 1995).
Vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)1 and 2 signaling is a potent activator of tumor angiogenesis. Although the expressions of VEGFR1 and VEGFR2 were initially thought to be limited to the endothelial cells, it is now known that both the receptors are expressed in tumor cells. This is the first study wherein VEGFRs-positive tumor cells are quantitatively evaluated for brain tumors with upregulated VEGF/VEGFR signaling. The percentage of VEGFRs-positive tumor cells was quantitatively evaluated in various brain tumors (10 glioblastomas, 22 neurofibromatosis type 2 [NF2]-related schwannomas, 21 sporadic schwannomas, 27 chordomas, 36 meningiomas, 29 hemangioblastomas, 11 hemangiopericytoma, and 13 ependymomas) using immunohistochemistry. VEGF-A expression was also analyzed using quantitative real-time polymerase chain reaction. Double immunofluorescence staining using anti-PDGFR-β and anti-CD34 antibody, microvessel density, and vessel diameter were analyzed to evaluate the vascular characteristics. Chordomas demonstrated an extremely higher percentage of VEGFR1 and VEGFR2-positive tumor cells than other tumors. In contrast, meningiomas and hemangiopericytomas showed few VEGFRs-positive tumor cells. The percentage of positive tumor cells in chordomas, hemangioblastomas, and NF2 schwannomas was associated with clinical courses, such as shorter progression free survival, and growth speed. Glioblastomas and NF2 schwannomas showed larger tumor vessels without pericyte coverage. The present study is the first to quantitatively analyze VEGFR1- and VEGFR2- positive tumor cells in various types of refractory brain tumors. This novel parameter significantly correlated with the progressive clinical courses.
Angiogenesis in brain tumors
2018, Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors
Angiogenesis, the formation of new blood vessels, is a complex process that involves the migration, growth, and differentiation of endothelial cells lining the inner walls of blood vessels.
Angiogenesis is a well-orchestrated process that is regulated by different proteins called angiogenic activators and inhibitors. In the central nervous system, angiogenesis is implicated in several conditions such as hypoxia, infarctions, infections, and cancers. Glioblastomas represent the most malignant brain tumors in adults and angiogenesis remains the most essential component for glioma survival, growth, and malignancy. A number of angiogenic factors, including vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, angiopoietin-2, and hepatocyte growth factor/scatter factor are crucial in glioblastoma angiogenesis. With the increasing knowledge about the important angiogenic mediators and signaling pathways, new targets have been identified that are therapeutically exploited in brain tumors. This chapter reviews the biology of angiogenesis, its implications in glioblastoma, and the therapeutic interventions that target angiogenesis in brain cancers.
Scleral penetration of an unusually aggressive case of a retinal hemangioblastoma
2013, Canadian Journal of Ophthalmology
Spinal Cord Tumors. New Views and Future Directions
2013, Neurologic Clinics
Citation Excerpt :
They compose about 2% to 8% of all intramedullary spinal cord tumors.4 The cell of origin is uncertain but likely vascular endothelial growth factor (VEGF)–secreting cells36 of undifferentiated mesenchymal origin.37 They occur sporadically in about 75% and are associated with von Hippel-Lindau disease in the remaining 25%.38
Hemangioblastoma of the filum terminale
2006, Journal of Clinical Neuroscience
A 52-year-old man presented with low backache, paraesthesiae and spasticity of both lower limbs. He had urinary retention and constipation. Investigations revealed a vascular intradural cauda equina-conus tumor. MRI scan demonstrated an enhancing mass at the second and third lumbar vertebral levels. There were multiple dilated and tortuous veins draining from both poles of the tumor. Digital subtraction spinal angiogram showed the tumor to be supplied mainly by the radiculo-medullary artery from first lumbar artery and dural branches of the second and third lumbar arteries. At surgery, after pre-operative embolization, a well-defined tumor with an orange hue and fleshy consistency was encountered arising from the filum terminale. The tumor was excised en bloc. A sporadic hemangioblastoma arising from the filum terminale should be considered as a rare cause of back pain and sciatica. Total excision of the tumor offers cure.

View all citing articles on Scopus

View full text

Regular ArticleExpression of Vascular Endothelial Growth Factor in Capillary Hemangioblastoma

Abstract

Regular Article
Expression of Vascular Endothelial Growth Factor in Capillary Hemangioblastoma